The efficacy of dopamine versus epinephrine for pediatric or neonatal septic shock: a meta-analysis of randomized controlled studies

Ital J Pediatr. 2020 Jan 14;46(1):6. doi: 10.1186/s13052-019-0768-x.

Abstract

Introduction: The efficacy of dopamine versus epinephrine for pediatric or neonatal septic shock remains controversial. We conduct a meta-analysis to explore the influence of dopamine versus epinephrine on shock reversal for pediatric or neonatal septic shock.

Methods: We have searched PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases through July 2019 for randomized controlled trials (RCTs) assessing the efficacy and safety of dopamine versus epinephrine for pediatric or neonatal septic shock.

Results: Three RCTs are included in the meta-analysis. Overall for pediatric or neonatal septic shock, dopamine and epinephrine reveal comparable shock reversal within 1 h (risk ratios (RR) = 0.61; 95% CI = 0.16 to 2.31; P = 0.47), mortality (RR = 1.16; 95% CI = 0.87 to 1.55; P = 0.30), heart rate (standard mean differences (SMD) = 0.03; 95% CI = -0.28 to 0.34; P = 0.85), systolic blood pressure (SMD = -0.18; 95% CI = -0.69 to 0.33; P = 0.49), mean arterial pressure (SMD = -0.15; 95% CI = -1.64 to 1.34; P = 0.84) and adverse events (RR = 1.00; 95% CI = 0.94 to 1.07; P = 0.91).

Conclusions: Dopamine and epinephrine show the comparable efficacy for the treatment of pediatric or neonatal septic shock.

Keywords: Dopamine; Epinephrine; Pediatric septic shock; Randomized controlled trials; Shock reversal.

Publication types

  • Meta-Analysis

MeSH terms

  • Child
  • Child, Preschool
  • Dopamine / therapeutic use*
  • Epinephrine / therapeutic use*
  • Humans
  • Infant
  • Infant, Newborn
  • Randomized Controlled Trials as Topic
  • Shock, Septic / drug therapy*
  • Vasoconstrictor Agents / therapeutic use*

Substances

  • Vasoconstrictor Agents
  • Dopamine
  • Epinephrine